Implementation of positron emission tomography (PET) targeting the prostate-specific membrane antigen (PSMA), a cell-surface transmembrane protein over-expressed in PCa cells [6], improves detection rates of recurrent PCa lesions even at low PSA levels and outside the prostatic fossa [7, 8]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.